2-[[6-[[17-(5,6-dihydroxy-6-methylheptan-2-yl)-11-hydroxy-4,4,9,13,14-pentamethyl-2,3,7,8,10,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-3,4,5-trihydroxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 2-[[6-[[17-(5,6-dihydroxy-6-methylheptan-2-yl)-11-hydroxy-4,4,9,13,14-pentamethyl-2,3,7,8,10,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-3,4,5-trihydroxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
• 化学式: C₄₂H₇₂O₁₄
• 分子量: 801.0
• InChiKey: SLAWMGMTBGDBFT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  56
• 可旋转键数：
  11
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  239
• 氢给体数：
  10
• 氢受体数：
  14

文献信息

• STAT3 and ERK signal pathway inhibitor comprising mogrosides and analogs thereof
  申请人：BEIJING UNIVERSITY OF AGRICULTURE

  公开号：US10617734B2

  公开（公告）日：2020-04-14

  The present invention relates to a chemical and pharmaceutical technology, and in particular to a STAT3 and ERK signal pathway inhibitor and a use thereof. The present invention provides a STAT3 and ERK signal pathway inhibitor. The inhibitor mainly consists of a mogroside and/or an analog thereof. The mogroside and the analog thereof inhibit the phosphorylation of a transcription factor STAT3 and the phosphorylation of an ERK. The method for preparing the mogroside and the analog has the characteristics of simpleness, strong operability and high purity of products. The present invention further provides a use of the STAT3 and ERK signal pathway inhibitor in the preparation of drugs for treating tumors, which realizes the purposes of inhibiting the proliferation of cancer cells and promoting the apoptosis of cancer cells and has a very good inhibition effect on cancers.

  本发明涉及一种化学和制药技术，尤其涉及一种 STAT3 和 ERK 信号通路抑制剂及其用途。本发明提供了一种 STAT3 和 ERK 信号通路抑制剂。该抑制剂主要由大戟甙和/或其类似物组成。该mogroside及其类似物可抑制转录因子STAT3的磷酸化和ERK的磷酸化。本发明制备莫高苷及其类似物的方法具有操作简单、可操作性强、产品纯度高等特点。本发明进一步提供了STAT3和ERK信号通路抑制剂在制备治疗肿瘤药物中的用途，实现了抑制癌细胞增殖和促进癌细胞凋亡的目的，对癌症具有很好的抑制作用。
• Cucurbitane tetracyclic triterpenoid compounds for application in treating pulmonary fibrosis
  申请人：CHENGDU BIOPURIFY LTD.

  公开号：US11179409B2

  公开（公告）日：2021-11-23

  An application of cucurbitane tetracyclic triterpenoid compounds in preparation of drugs and/or health products for preventing and/or treating pulmonary fibrosis is provided, which is a new medicine use of cucurbitane tetracyclic triterpenoid compounds.

  本发明提供了葫芦科四环三萜类化合物在制备预防和/或治疗肺纤维化的药物和/或保健品中的应用，这是葫芦科四环三萜类化合物的一种新的医药用途。
• Production of mogroside compounds in recombinant hosts
  申请人：EVOLVA SA

  公开号：US11248248B2

  公开（公告）日：2022-02-15

  The invention relates to recombinant microorganisms and methods for producing mogroside compounds and mogroside precursors.

  本发明涉及重组微生物和生产茂甙化合物及茂甙前体的方法。
• STAT3 AND ERK SIGNAL PATHWAY INHIBITOR AND USE THEREOF
  申请人：BEIJING UNIVERSITY OF AGRICULTURE

  公开号：US20170368130A1

  公开（公告）日：2017-12-28

  The present invention relates to a chemical and pharmaceutical technology, and in particular to a STAT3 and ERK signal pathway inhibitor and a use thereof. The present invention provides a STAT3 and ERK signal pathway inhibitor. The inhibitor mainly consists of a mogroside and/or an analog thereof. The mogroside and the analog thereof inhibit the phosphorylation of a transcription factor STAT3 and the phosphorylation of an ERK. The method for preparing the mogroside and the analog has the characteristics of simpleness, strong operability and high purity of products. The present invention furtherprovides a use of the STAT3 and ERK signal pathway inhibitor in the preparation of drugs for treating tumors, which realizes the purposes of inhibiting the proliferation of cancer cells and promoting the apoptosis of cancer cells and has a very good inhibition effect on cancers.
• Production of Mogroside Compounds in Recombinant Hosts
  申请人：EVOLVA SA

  公开号：US20200165652A1

  公开（公告）日：2020-05-28

  The invention relates to recombinant microorganisms and methods for producing mogroside compounds and mogroside precursors.